Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apraglutide multiple-dose study of gastric emptying of liquids in healthy volunteers
NL-OMON53626Phase 1Recruiting
- Sponsor
- VectivBio
- Start
- Mar 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in short bowel syndrome (SBS) and graft-versus-host disease (GVHD) comparing Apraglutide with Placebo (2 arms). Primary endpoint: Effect of apraglutide on gastric emptying of liquids. Started Mar 2023; status: recruiting.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NL-OMON53626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53626.